GR851114B - - Google Patents

Info

Publication number
GR851114B
GR851114B GR851114A GR850101114A GR851114B GR 851114 B GR851114 B GR 851114B GR 851114 A GR851114 A GR 851114A GR 850101114 A GR850101114 A GR 850101114A GR 851114 B GR851114 B GR 851114B
Authority
GR
Greece
Prior art keywords
active agent
diffusion
gradient
release
environment
Prior art date
Application number
GR851114A
Other languages
Greek (el)
English (en)
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of GR851114B publication Critical patent/GR851114B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Colloid Chemistry (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines Containing Plant Substances (AREA)
GR851114A 1984-05-10 1985-05-08 GR851114B (en:Method)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/608,756 US4624848A (en) 1984-05-10 1984-05-10 Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use

Publications (1)

Publication Number Publication Date
GR851114B true GR851114B (en:Method) 1985-11-25

Family

ID=24437841

Family Applications (1)

Application Number Title Priority Date Filing Date
GR851114A GR851114B (en:Method) 1984-05-10 1985-05-08

Country Status (16)

Country Link
US (1) US4624848A (en:Method)
EP (1) EP0164311B1 (en:Method)
JP (1) JPS619A (en:Method)
AT (1) ATE61731T1 (en:Method)
AU (1) AU583507B2 (en:Method)
CA (1) CA1246447A (en:Method)
DE (1) DE3582193D1 (en:Method)
DK (1) DK205185A (en:Method)
ES (1) ES8603273A1 (en:Method)
FI (1) FI851801A7 (en:Method)
GR (1) GR851114B (en:Method)
IL (1) IL75129A (en:Method)
NZ (1) NZ212030A (en:Method)
PH (1) PH24100A (en:Method)
PT (1) PT80416B (en:Method)
ZA (1) ZA853511B (en:Method)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749576A (en) * 1984-05-10 1988-06-07 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
JPS61218517A (ja) * 1985-03-25 1986-09-29 Bio Materiaru Yunibaasu:Kk 経皮吸収製剤
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US4794002A (en) * 1985-11-01 1988-12-27 Monsanto Company Modified polymeric surfaces and process for preparing same
JPH0643851B2 (ja) * 1986-03-13 1994-06-08 大同メタル工業株式会社 軸受ユニット
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4780236A (en) * 1986-06-20 1988-10-25 Kiwi Brands, Inc. Lavoratory cleansing block containing polyethylene gycol disteatrate, guar gum and sodium chloride
US4743248A (en) * 1986-08-11 1988-05-10 Alza Corporation Dosage form for delivering acid sensitive beneficial agent
GB8620845D0 (en) * 1986-08-28 1986-10-08 Reckitt & Colmann Prod Ltd Treatment of textile surfaces
EP0297650A1 (en) * 1987-06-26 1989-01-04 Duphar International Research B.V Compositions with controlled zero-order delivery rate and method of preparing these compositions
US5219575A (en) * 1987-06-26 1993-06-15 Duphar International Research B.V. Compositions with controlled zero-order delivery rate and method of preparing these compositions
US4910015A (en) * 1987-10-19 1990-03-20 Massachusetts Institute Of Technology Surface-active polysiloxanes and drug releasing materials thereof
GB8801863D0 (en) * 1988-01-28 1988-02-24 Fulmer Yarsley Ltd Pharmaceutical formulations with controlled drug release
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
JPH10513471A (ja) 1995-02-10 1998-12-22 メドトロニック、インコーポレイテッド 鎮痛薬投与のための方法と装置
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US6039968A (en) * 1997-06-24 2000-03-21 Hoechst Marion Roussel Intravaginal drug delivery device
DE19843904A1 (de) * 1998-09-24 2000-03-30 Basf Ag Feste Dosierungsform mit polymerem Bindemittel
DE19843903A1 (de) * 1998-09-24 2000-03-30 Basf Ag Feste Dosierungsform mit copolymerem Bindemittel
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US7943162B2 (en) * 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
GEP20043334B (en) * 1999-12-23 2004-03-10 Pfizer Prod Inc Hydrogel-Driven Drug Dosage Form
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
ES2278936T3 (es) 2001-07-23 2007-08-16 Alcon, Inc. Dispositivo de administracion de farmacos oftalmicos.
CA2446741C (en) * 2001-07-23 2009-09-29 Alcon, Inc. Ophthalmic drug delivery device
CA2464653C (en) * 2001-10-29 2011-10-18 Therics, Inc. System for manufacturing controlled release dosage forms, such as a zero-order release profile dosage form manufactured by three-dimensional printing
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
GB0310636D0 (en) * 2003-05-08 2003-06-11 Nektar Therapeutics Uk Ltd Particulate materials
US7354601B2 (en) 2003-05-08 2008-04-08 Walker Stephen E Particulate materials
BRPI0410542A (pt) * 2003-07-10 2006-06-20 Alcon Inc dispositivo de administração de medicamento para um olho e método de administrar um agente farmaceuticamente ativo a um olho
US20060246109A1 (en) * 2005-04-29 2006-11-02 Hossainy Syed F Concentration gradient profiles for control of agent release rates from polymer matrices
ES2713062T3 (es) 2005-09-27 2019-05-17 Tissuetech Inc Preparaciones de membrana amniótica y composiciones purificadas y métodos de uso
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
WO2007062266A2 (en) 2005-11-28 2007-05-31 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof
US8246973B2 (en) 2006-06-21 2012-08-21 Advanced Cardiovascular Systems, Inc. Freeze-thaw method for modifying stent coating
JP2009543902A (ja) 2006-07-10 2009-12-10 メディパックス インコーポレイテッド 超弾性エポキシヒドロゲル
ATE510538T1 (de) 2006-08-11 2011-06-15 Univ Johns Hopkins Zusammensetzungen und verfahren für nervenschutz
ES2585902T3 (es) 2006-09-22 2016-10-10 Pharmacyclics Llc Inhibidores de tirosina cinasa de Bruton
US8263641B2 (en) 2007-09-10 2012-09-11 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP2011505520A (ja) 2007-12-03 2011-02-24 メディパックス インコーポレイテッド 流体計量供給装置
EP2321303B1 (en) 2008-08-27 2019-11-27 Calcimedica, Inc. Compounds that modulate intracellular calcium
CA2758571A1 (en) 2009-04-24 2010-10-28 Tissuetech, Inc. Compositions containing hc-ha complex and methods of use thereof
WO2011032011A1 (en) 2009-09-10 2011-03-17 Medipacs, Inc. Low profile actuator and improved method of caregiver controlled administration of therapeutics
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
US9500186B2 (en) 2010-02-01 2016-11-22 Medipacs, Inc. High surface area polymer actuator with gas mitigating components
ES2602475T3 (es) 2010-04-15 2017-02-21 Tracon Pharmaceuticals, Inc. Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
DK2563776T3 (en) 2010-04-27 2016-09-19 Calcimedica Inc Relations that modulate intracellular calcium
JP2013525448A (ja) 2010-04-27 2013-06-20 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
NZ702485A (en) 2010-06-03 2016-04-29 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
WO2012027710A2 (en) 2010-08-27 2012-03-01 Calcimedica Inc. Compounds that modulate intracellular calcium
US8668675B2 (en) 2010-11-03 2014-03-11 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
CA2767773C (en) 2011-02-11 2015-11-24 Grain Processing Corporation Composition comprising a salt and a crystallization interrupter
WO2012149486A1 (en) 2011-04-28 2012-11-01 Tissuetech, Inc. Methods of modulating bone remodeling
ES2822301T3 (es) 2011-06-10 2021-04-30 Tissuetech Inc Métodos de procesamiento de tejidos de soporte fetal
KR101892788B1 (ko) 2011-09-13 2018-08-28 파마싸이클릭스 엘엘씨 벤다무스틴과 조합된 히스톤 디아세틸라제 억제제의 제제 및 그의 용도
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
JP2015508407A (ja) 2012-01-06 2015-03-19 アビデ セラピューティクス，インク． カルバメート化合物およびその製造および使用
HK1206374A1 (en) 2012-03-14 2016-01-08 麦德医像公司 Smart polymer materials with excess reactive molecules
BR112014030424A8 (pt) 2012-06-04 2017-07-11 Pharmacyclics Inc Formas cristalinas de um inibidor de quinase de tirosina de bruton
CN104619352B (zh) 2012-07-11 2022-02-18 组织技术公司 含有hc-ha/ptx3复合物的组合物及其使用方法
CA2885828C (en) 2012-09-28 2021-04-27 University Of Washington Through Its Center For Commercialization Ureido-thiophenyl derivatives, compositions thereof and methods for preventing, treating and/or protecting against sensory hair cell death
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
CA2932609A1 (en) 2013-12-05 2015-06-11 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2015164213A1 (en) 2014-04-23 2015-10-29 The Research Foundation For The State University Of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
US10080877B2 (en) 2014-07-25 2018-09-25 Warsaw Orthopedic, Inc. Drug delivery device and methods having a drug cartridge
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
ES2760373T3 (es) 2015-02-06 2020-05-13 Univ Washington Compuestos y procedimientos para prevenir o tratar la muerte de células ciliadas sensoriales
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
US20160243288A1 (en) 2015-02-23 2016-08-25 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
CN107530304A (zh) 2015-02-27 2018-01-02 科泰纳制药公司 Olig2活性的抑制
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
MA41827A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
MA41828A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
CA2984480A1 (en) 2015-05-11 2016-11-17 Abide Therapeutics, Inc. Methods of treating inflammation or neuropathic pain
TWI720984B (zh) 2015-05-20 2021-03-11 美商帝聖工業公司 用於防止上皮細胞增生及上皮-間質轉移之組合物及方法
HK1256718A1 (zh) 2015-08-31 2019-10-04 药品循环有限责任公司 用於治疗多发性骨髓瘤的btk抑制剂组合
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
US10975149B2 (en) 2015-12-16 2021-04-13 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced SH2 protein in NK cells
CA3008338A1 (en) 2016-01-19 2017-07-27 Janssen Pharmaceutica Nv Formulations/compositions comprising a btk inhibitor
AU2017208473B2 (en) 2016-01-19 2022-04-21 Janssen Pharmaceutica Nv Formulations/compositions comprising a BTK inhibitor
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
DK3442538T3 (da) 2016-04-04 2025-09-01 Sinopia Biosciences Inc Behandling af levodopa-induceret dyskinesi med trapidil
US10821105B2 (en) 2016-05-25 2020-11-03 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
US10549081B2 (en) 2016-06-23 2020-02-04 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
WO2018005600A1 (en) * 2016-06-28 2018-01-04 Trustees Of Tufts College Compositions and methods for delivery of active agents
CN116332886A (zh) 2016-07-18 2023-06-27 广州瑞安博医药科技有限公司 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法
US11242323B2 (en) 2016-08-26 2022-02-08 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
PE20191239A1 (es) 2016-11-16 2019-09-16 Abide Therapeutics Inc Formas cristalinas de un inhibidor de magl
MY199448A (en) 2016-11-16 2023-10-29 H Lundbeck As Pharmaceutical formulations
AU2018325267B2 (en) 2017-09-01 2023-03-30 University Of Washington Crystalline forms of compounds for preventing or treating sensory hair cell death
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
US10717712B2 (en) 2018-07-27 2020-07-21 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic TRPV1 agonists
EP3890722A4 (en) 2018-12-06 2022-08-24 Arthrosi Therapeutics, Inc. METHODS OF TREATMENT OR PREVENTION OF GOUT OR HYPERURICEMIA
EA202191545A1 (ru) 2018-12-06 2021-10-28 Артроси Терапьютикс, Инк. Кристаллические формы соединения для лечения или профилактики подагры или гиперурикемии
AU2019417833B2 (en) 2018-12-31 2024-11-07 Biomea Fusion, Inc. Irreversible inhibitors of menin-MLL interaction
MX2021011081A (es) 2019-03-15 2022-01-18 Unicycive Therapeutics Inc Derivados de nicorandil.
TW202202502A (zh) 2020-03-26 2022-01-16 美商斯諾皮亞生物科學公司 經同位素標記之曲匹地(trapidil)衍生物
BR112021025516A2 (pt) 2020-04-21 2022-11-01 H Lundbeck As Processos para a fabricação de 4-(2-(pirrolidin-1-il)-4-(trifluorometil)benzil)piperazina-1-carboxilato de 1,1,1,3,3,3-hexafluoropropan-2-ila e da forma 2 do sal monocloridrato do mesmo
CN116234804A (zh) 2020-05-11 2023-06-06 克立弗治疗学股份有限公司 VCP/p97抑制剂的结晶形式和制剂
WO2022133064A1 (en) 2020-12-16 2022-06-23 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
WO2022150525A1 (en) 2021-01-06 2022-07-14 Awakn Life Sciences Mdma in the treatment of alcohol use disorder
WO2022238507A1 (en) 2021-05-11 2022-11-17 Awakn Ls Europe Holdings Limited Therapeutic aminoindane compounds and compositions
EP4346788A4 (en) 2021-06-03 2025-04-30 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
CA3228627A1 (en) 2021-08-11 2023-02-16 Thomas Butler Covalent inhibitors of menin-mll interaction for diabetes mellitus
AU2022331496A1 (en) 2021-08-20 2024-02-29 Biomea Fusion, Inc. Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
WO2023028091A1 (en) 2021-08-23 2023-03-02 Alexander Shulgin Research Institute Deuterated empathogens
IL311051A (en) 2021-08-23 2024-05-01 Alexander Shulgin Res Institute Inc Fluorinated empathogens
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
KR20240054333A (ko) 2021-08-31 2024-04-25 세레스파이어 인코포레이티드 공결정
EP4396162A4 (en) 2021-09-03 2025-11-12 Alexander Shulgin Res Institute Inc ASYMMETRIC ALLYL TRYPTAMINES
US20240409558A1 (en) 2021-09-13 2024-12-12 Biomea Fusion, Inc. Irreversible inhibitors of kras
CA3232827A1 (en) 2021-09-25 2023-03-30 Paul Daley Substituted phenylalkylamines
US20250066386A1 (en) 2021-11-09 2025-02-27 Biomea Fusion, Inc. Inhibitors of kras
MX2024008057A (es) 2021-12-30 2024-08-28 Biomea Fusion Inc Compuestos de pirazina como inhibidores de flt3.
CA3249142A1 (en) 2022-01-19 2023-07-27 Awakn Ls Europe Holdings Limited 1,3-BENZODIOXOLE ESTERS AND THEIR THERAPEUTIC USE
CA3244485A1 (en) 2022-02-16 2023-08-24 Awakn Ls Europe Holdings Limited BRIDGED CYCLIC COMPOUNDS AND THEIR THERAPEUTIC USE AS CNS AGENTS
US20250353854A1 (en) 2022-06-03 2025-11-20 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
EP4551573A1 (en) 2022-07-06 2025-05-14 Oppilan Pharma Ltd. Crystalline forms of an s1p receptor modulator
WO2024155710A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction
US20250002458A1 (en) 2023-05-24 2025-01-02 Unicycive Therapeutics Inc. Salt forms of nicorandil derivative
WO2024249950A1 (en) 2023-06-02 2024-12-05 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
WO2025072556A1 (en) 2023-09-26 2025-04-03 Unicycive Therapeutics, Inc. Amino acid prodrugs of nicorandil
WO2025194102A1 (en) 2024-03-15 2025-09-18 Unicycive Therapeutics, Inc. Pyridine modified nicorandil derivatives

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH468192A (de) * 1964-06-19 1969-02-15 Ciba Geigy Verfahren zur Herstellung von Arzneimitteln in Perlenform
IT1050353B (it) * 1966-01-06 1981-03-10 Ceskoslovenska Akademie Ved Supporti per sostanze biologigamente attive
US3660071A (en) * 1966-07-26 1972-05-02 Nat Patent Dev Corp Water soluble entrapping of a pesticide
US3660563A (en) * 1966-07-26 1972-05-02 Nat Patent Dev Corp Water soluble entrapping of a drug
US3577512A (en) * 1968-10-11 1971-05-04 Nat Patent Dev Corp Sustained release tablets
US3576760A (en) * 1969-06-13 1971-04-27 Nat Patent Dev Corp Water soluble entrapping
DE2031871C3 (de) * 1970-06-27 1974-06-27 Roehm Gmbh, 6100 Darmstadt Überzugsmasse für Arzneiformen
GB1394990A (en) * 1971-08-12 1975-05-21 Hydrophilics Int Inc Copolymers and compositions containing copolymers
US4056496A (en) * 1972-10-02 1977-11-01 Corneal Sciences, Inc. Hydrogels and articles made therefrom
US4070348A (en) * 1973-07-25 1978-01-24 Rohm Gmbh Water-swellable, bead copolymer
US4178361A (en) * 1973-09-10 1979-12-11 Union Corporation Sustained release pharmaceutical composition
US4007258A (en) * 1973-09-10 1977-02-08 Union Corporation Sustained release pesticidal composition
CH621561A5 (en) * 1974-01-14 1981-02-13 Ceskoslovenska Akademie Ved Process for producing a bromocyan-activated, hydrophilic, polymeric carrier for biologically active compounds in dried form
US3923939A (en) * 1974-06-07 1975-12-02 Alza Corp Process for improving release kinetics of a monolithic drug delivery device
US4177056A (en) * 1974-06-27 1979-12-04 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides
US4248855A (en) * 1976-08-27 1981-02-03 Hydrophilics International, Inc. Pharmaceutical base salts
US4164560A (en) * 1977-01-05 1979-08-14 Folkman Moses J Systems for the controlled release of macromolecules
US4304591A (en) * 1978-01-25 1981-12-08 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides
DE2908794C2 (de) * 1978-03-09 1984-09-13 Japan Atomic Energy Research Institute, Tokio/Tokyo Verfahren zur Herstellung eines eine physiologisch aktive Substanz enthaltenden Polymerpräparates
US4267295A (en) * 1979-02-09 1981-05-12 Syntex (U.S.A.) Inc. Polymeric compositions and hydrogels formed therefrom
US4357312A (en) * 1981-07-16 1982-11-02 The Children's Hospital Medical Center Method of making prolonged release body
IL70071A (en) * 1982-11-01 1987-12-31 Merrell Dow Pharma Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient
US4564364A (en) * 1983-05-26 1986-01-14 Alza Corporation Active agent dispenser
GB8319766D0 (en) * 1983-07-22 1983-08-24 Graham N B Controlled release device

Also Published As

Publication number Publication date
NZ212030A (en) 1988-01-08
PT80416A (en) 1985-06-01
FI851801A0 (fi) 1985-05-08
PT80416B (en) 1987-04-16
JPS619A (ja) 1986-01-06
US4624848A (en) 1986-11-25
DK205185D0 (da) 1985-05-09
FI851801L (fi) 1985-11-11
ES542948A0 (es) 1986-01-01
IL75129A (en) 1989-08-15
ZA853511B (en) 1985-12-24
AU583507B2 (en) 1989-05-04
EP0164311A3 (en) 1987-06-03
ES8603273A1 (es) 1986-01-01
DK205185A (da) 1985-11-11
AU4221685A (en) 1985-11-14
CA1246447A (en) 1988-12-13
IL75129A0 (en) 1985-09-29
DE3582193D1 (de) 1991-04-25
FI851801A7 (fi) 1985-11-11
ATE61731T1 (de) 1991-04-15
PH24100A (en) 1990-03-05
EP0164311B1 (en) 1991-03-20
EP0164311A2 (en) 1985-12-11

Similar Documents

Publication Publication Date Title
GR851114B (en:Method)
GR851844B (en:Method)
EP0013606A3 (en) Polymeric diffusion matrix, method of its preparation and drug delivery device comprising said matrix
EP0213083A3 (en) Controlled release tablet
IE900470L (en) Medicaments having controlled release of the active¹compound
GB2146531B (en) Controlled release system
DE69531773D1 (de) Vorrichtung zur verabreichung von nützlichen stoffen an wiederkäuer
ES2194232T3 (es) Reservorio de espuma polimerica para dispositivo de aporte por electrotransporte.
ES8402806A1 (es) Procedimiento para la preparacion de fertilizantes con comienzo controlado de la cesion de substancias nutricias.
ATE68686T1 (de) System zum freigeben von stoffen in der vagina.
ES8601756A1 (es) Metodo de fabricar una estructura compuesta coherente.
JPS52130980A (en) Immobilization of glucoseisomerase
MX5150E (es) Procedimiento para preparar un copolimero de bloque hidrofilico que contiene un agente biologicamente activo